BroadOak Capital Partners

BroadOak Capital Partners, LLC is a privately held investment bank based in Bethesda, Maryland, specializing in the life sciences sector. Founded in 2006, the firm provides a range of advisory services, including mergers and acquisitions, divestitures, business combinations, capital formation, and valuations. BroadOak focuses on growth-stage companies within various areas of the life sciences, such as research tools and consumables, diagnostics, therapeutics, healthcare IT, pharmaceutical services, and medical devices. The firm is committed to supporting the development of innovative solutions in the industry, particularly in emerging fields like cell and gene therapy and single-cell genomics.

Michael Caspani

Managing Director, Investments

Henry Dervishi

Associate

Austin Duke

Managing Director, Investments

Daniel Friedman

Vice President, Investments

Lars Hanan

Partner, Advisory Team

Kathleen Manapat

Associate, Advisory Team

Matthew McFarland

Managing Director

Anup Parikh Ph.D

Operating Partner, Investment Team

Bill Snider

Partner

Robert Wicke

Operating Partner

Kyle Wilson

Partner, Advisory Team

29 past transactions

PBS Biotech

Venture Round in 2025
PBS Biotech specializes in the manufacture of single-use bioreactor systems designed to create homogeneous and scalable mixing conditions for various cell therapy products and cell culture applications. The company offers innovative disposable vessels and bags, alongside process development services that include cell therapy optimization, characterization, and risk analysis. By providing efficient and cost-effective solutions, PBS Biotech enables biotechnology firms to enhance operational efficiency, reduce costs, and effectively address their cell therapy requirements. Their bioreactors are notable for having the smallest per liter volume footprints, making them fully scalable for all stages of the cell culture process, from research and development to clinical and cGMP production. Through their technical expertise and commitment to solving complex cell culture challenges, PBS Biotech supports its clients in achieving their manufacturing goals.

S2 Genomics

Series A in 2024
S2 Genomics, Inc. is a biotechnology company that specializes in developing integrated sample preparation systems for genomic analyses. Founded in 2016 and headquartered in Livermore, California, the company focuses on spatial sequencing technology that captures the three-dimensional coordinates of single cells within tissues. S2 Genomics' solutions automate the processing of solid tissues into single cells or nuclei, which enhances the efficiency and reproducibility of genomic studies. By enabling researchers to isolate viable cells with minimal impact on the cellular transcriptome, the company aims to improve the quality and quantity of samples available for genomics and cell biology research.

Pluristyx

Venture Round in 2023
Pluristyx specializes in advanced cell therapy tools and consulting services aimed at addressing manufacturing challenges in drug development, regenerative medicine, and cell and gene therapy. The company offers comprehensive services including CMC consulting, pluripotent stem cell manufacturing, and contract development and manufacturing. By providing unique products and expert guidance, Pluristyx supports clients in accelerating the development and commercialization of innovative therapeutics designed to treat serious human diseases. Through its specialized knowledge and tools, the company plays a crucial role in advancing the field of cell and gene therapy.

Telesis Bio

Post in 2023
Telesis Bio is a biotechnology company founded in 2013 and based in San Diego, USA. It specializes in synthetic biology, providing researchers with tools to design, create, and secure synthetic DNA and mRNA. The company focuses on enabling the rapid, accurate, and reproducible synthesis of high-quality synthetic genetic materials for various applications in synthetic biology. Telesis Bio manufactures and sells a range of laboratory equipment, including synthetic biology instruments and reagents, as well as offering related services. Its product lineup features the BioXp system, BioXp kits, and Benchtop reagents, alongside BioXp biofoundry services, all aimed at supporting innovative research and development in the field.

Sanguine

Venture Round in 2023
Sanguine is a company focused on enhancing translational biomedical research by facilitating patient participation. It aims to bridge the gap between patients and researchers by offering personalized medicine solutions and a range of tools and concierge services. Sanguine empowers patients to engage in research from the comfort of their homes while ensuring transparency throughout the research process. The company's approach emphasizes respectful patient support and appropriate compensation, fostering a positive experience for participants and yielding more impactful biospecimens for research. Through its efforts, Sanguine seeks to improve the development of new treatments by actively involving patients in the medical research landscape.

CDI Labs

Acquisition in 2023
CDI Labs, the result of intensive efforts and advances developed by the High-Throughput Biology Center at Johns Hopkins University, is a privately owned research and discovery company in the field of proteomics. The company was created by scientists for scientists, addressing the critical needs required in order to accelerate research, advance discoveries and translate these discoveries into novel products and services that improve human health.The company applies its accelerating platforms to internal, collaborative, and client programs.

PBS Biotech

Venture Round in 2023
PBS Biotech specializes in the manufacture of single-use bioreactor systems designed to create homogeneous and scalable mixing conditions for various cell therapy products and cell culture applications. The company offers innovative disposable vessels and bags, alongside process development services that include cell therapy optimization, characterization, and risk analysis. By providing efficient and cost-effective solutions, PBS Biotech enables biotechnology firms to enhance operational efficiency, reduce costs, and effectively address their cell therapy requirements. Their bioreactors are notable for having the smallest per liter volume footprints, making them fully scalable for all stages of the cell culture process, from research and development to clinical and cGMP production. Through their technical expertise and commitment to solving complex cell culture challenges, PBS Biotech supports its clients in achieving their manufacturing goals.

Halo Labs

Series C in 2022
Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

seqWell

Series C in 2022
seqWell Inc. is a biotechnology company based in Beverly, Massachusetts, specializing in sequencing services and library preparation workflows. Founded in 2014, seqWell offers a range of products, including paramagnetic beads for nucleic acid purification and library preparation kits. The company has developed a transformative technology platform that enables simple and scalable multiplexing of hundreds to thousands of samples, significantly reducing the time and costs associated with normalization. In addition to its products, seqWell provides comprehensive biological library preparation, sequencing, data processing, and customized bioinformatics support services. Its offerings are distributed in various countries, including the United States, Australia, South Korea, and several European nations, as well as through online channels.

Genomenon

Series B in 2022
Genomenon, Inc. is a software development company based in Ann Arbor, Michigan, that specializes in tools for genetic diagnosis and discovery. Founded in 2014, it provides a suite of diagnostic and discovery solutions that enable physicians, researchers, and pharmaceutical companies to rapidly and accurately identify disease-causing variants from genomic sequencing data. The company’s flagship product, GENOMENON, automates the analysis of next-generation sequencing data, thereby enhancing decision-making processes in clinical settings and accelerating discoveries in genomics. With its focus on improving cancer diagnosis and treatment, Genomenon aims to support better patient outcomes through its innovative software solutions.

Avidien Technologies

Venture Round in 2022
Avidien Technologies is a manufacturer of innovative liquid handling instruments designed to enhance the efficiency and accuracy of laboratory research. The company specializes in a range of products, including semi-automated pipettes and compact laboratory instruments. Notably, their microPro 300 pipette features a wirelessly connected iPad mini interface, which integrates advanced technology into a user-friendly design. Avidien Technologies aims to provide researchers and scientists with reliable, affordable, and easy-to-use solutions that improve their work processes and overall productivity in the laboratory environment.

PhenoVista Biosciences

Venture Round in 2022
PhenoVista Biosciences is a specialized contract research organization that focuses on high content imaging-based phenotypic assay development and screening services. The company employs advanced technology to conduct feasibility studies, assay development, and comprehensive screening campaigns. By leveraging various human cell models and different cell types, PhenoVista provides insights into disease mechanisms across fields such as neurobiology, oncology, and mitochondrial health. Its dedicated team of cell biologists collaborates closely with clients to deliver timely and cost-effective data, thereby supporting the development of new formulations and therapeutic strategies.

Accellix

Series E in 2021
Accellix, Inc. is a biotechnology company specializing in the development of microflow cytometer systems for diagnostic applications. Founded in 2009 and headquartered in San Jose, California, with an additional office in Jerusalem, the company creates compact, table-top flow cytometry instruments that utilize microfluidics technology. These instruments are designed for point-of-care testing and include disposable, single-use cartridges tailored for specific tests. Accellix's products enable rapid and accurate diagnostic results, particularly for applications such as early detection and monitoring of blood infections, as well as HIV/AIDS. The company's innovative platform also supports quality control requirements for cell and gene therapy, offering automated sample preparation that enhances reproducibility and accuracy in laboratory settings.

Gemini Bio-Products

Private Equity Round in 2021
Gemini Bio-Products specializes in manufacturing biological products and chemical reagents for the global cell culture community. The company provides a variety of cell culture sera, including fetal bovine, specialized fetal bovine, as well as other non-fetal, human, and animal sera. In addition to sera, Gemini Bio-Products offers custom and specialized media, along with a range of supplements and reagents. Their product line includes amino acids, antibiotics, antimycotics, culture supplements, albumins, recombinant proteins, attachment factors, and cell dissociation reagents, catering to diverse needs within the cell culture sector.

PBS Biotech

Venture Round in 2021
PBS Biotech specializes in the manufacture of single-use bioreactor systems designed to create homogeneous and scalable mixing conditions for various cell therapy products and cell culture applications. The company offers innovative disposable vessels and bags, alongside process development services that include cell therapy optimization, characterization, and risk analysis. By providing efficient and cost-effective solutions, PBS Biotech enables biotechnology firms to enhance operational efficiency, reduce costs, and effectively address their cell therapy requirements. Their bioreactors are notable for having the smallest per liter volume footprints, making them fully scalable for all stages of the cell culture process, from research and development to clinical and cGMP production. Through their technical expertise and commitment to solving complex cell culture challenges, PBS Biotech supports its clients in achieving their manufacturing goals.

KromaTiD

Venture Round in 2021
KromaTiD, Inc. is an early-stage bioscience company based in Fort Collins, Colorado, specializing in chromosome analysis for biomedical research and medical testing. Incorporated in 2007, the company develops advanced molecular cytogenetics assays and reagents that focus on detecting genetic abnormalities, including inversions and translocations. Utilizing its proprietary Directional Genomic Hybridization (dGH) technology, KromaTiD offers a range of products, including chromosome imaging tools, assays for targeting entire chromosomes or individual chromatids, and inversion detection solutions. Its dGH assays generate critical sequence, location, and orientation data from single cells, making them suitable for studies involving mixed cell populations. KromaTiD's innovations aim to enhance the understanding of genetic diseases, facilitating the development of novel therapeutics in oncology and rare diseases.

Genomenon

Series A in 2021
Genomenon, Inc. is a software development company based in Ann Arbor, Michigan, that specializes in tools for genetic diagnosis and discovery. Founded in 2014, it provides a suite of diagnostic and discovery solutions that enable physicians, researchers, and pharmaceutical companies to rapidly and accurately identify disease-causing variants from genomic sequencing data. The company’s flagship product, GENOMENON, automates the analysis of next-generation sequencing data, thereby enhancing decision-making processes in clinical settings and accelerating discoveries in genomics. With its focus on improving cancer diagnosis and treatment, Genomenon aims to support better patient outcomes through its innovative software solutions.

Halo Labs

Series B in 2020
Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

seqWell

Series B in 2020
seqWell Inc. is a biotechnology company based in Beverly, Massachusetts, specializing in sequencing services and library preparation workflows. Founded in 2014, seqWell offers a range of products, including paramagnetic beads for nucleic acid purification and library preparation kits. The company has developed a transformative technology platform that enables simple and scalable multiplexing of hundreds to thousands of samples, significantly reducing the time and costs associated with normalization. In addition to its products, seqWell provides comprehensive biological library preparation, sequencing, data processing, and customized bioinformatics support services. Its offerings are distributed in various countries, including the United States, Australia, South Korea, and several European nations, as well as through online channels.

InFuse Holdings

Series A in 2019
InFuse Holdings operates ambulatory infusion centers that focus on delivering high-quality, cost-effective infusion therapies to patients. Recognizing the deficiencies in the existing infrastructure for infusion services across the United States, the company aims to enhance patient care by implementing best practices in areas such as workflow, inventory management, scheduling, safety protocols, staffing, and customer experience. By providing a safe and convenient environment for complex biologic infusion therapies, InFuse Holdings is able to offer these services at a lower cost than traditional delivery methods. This cost-effective model not only benefits patients but also helps employers and payers reduce overall healthcare expenses.

Codex DNA

Series A in 2019
Codex DNA is a biology company helping researchers with the tools they need to securely design, code, and create synthetic DNA. The company is on a mission to help scientific researchers in both academic and commercial settings with the hardware, software, materials, and methodologies required to rapidly and accurately write large quantities of synthetic genes. To, in effect, build biology. Its gene synthesis portfolio reduces the turnaround time for synthesizing workflows from weeks and months to days and hours and includes the BioXp system, DNA services, Gibson Assembly reagents, and Vmax chemically competent cells. In addition to automating, speeding, and optimizing DNA design and synthesis, Codex DNA and the BioXp system ensure your designs stay in your hands, marrying speed and security for innovators in drug discovery, vaccine development, precision medicine, and beyond. Co-founded by Dan Gibson — the creator of the industry-standard Gibson Assembly methodology — Codex DNA is attempting nothing less than changing everything.

Halo Labs

Series B in 2018
Halo Labs is a life science instrumentation company based in Burlingame, California, specializing in the development of tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technologies. Halo Labs' offerings include assessment of biologics-developability, formulation development, late-stage formulation, small molecule solubility, and AAV analytics. Founded in 2011, the company has gained recognition for its innovative scientific platform, which provides critical insights into the particles involved in research processes, thereby enhancing the stability and quality assessment of biological drugs.

BioInformatics

Series B in 2018
BioInformatics LLC is a market research and advisory company established in 1994, headquartered in Arlington, Virginia. It serves the life science, medical device, pharmaceutical, and diagnostic industries globally. The company specializes in assessing market size and attractiveness, optimizing product configurations and pricing strategies, validating corporate acquisitions, measuring brand loyalty, evaluating brand strength and positioning, and forecasting markets and technologies. BioInformatics offers custom research services such as product concept testing, customer satisfaction analysis, market attractiveness studies, and brand awareness assessments. Its clients include biotechnology companies, medical diagnostics firms, pharmaceutical corporations, professional services providers, publishers, and associations. The company's team comprises industry veterans, market research experts, consultants, and survey statisticians.

MedCision

Acquisition in 2018
MedCision is a leading company in automated cell thawing technologies for advanced therapies, specializing in the development and commercialization of solutions that enhance the handling of biologics in preclinical and clinical settings. Its flagship product, the ThawSTAR® Automated Cell Thawing System, replaces traditional manual thawing methods with a controlled, standardized process that minimizes variability and risks associated with therapeutic cell thawing. This system utilizes customizable algorithms tailored to specific cell therapy products, ensuring optimal cell efficacy. In addition, MedCision offers ultra-low temperature cold storage and transport solutions, facilitating the effective management of temperature-sensitive biotherapeutic products. Through these innovations, MedCision aims to improve near-patient drug management, ultimately supporting healthcare professionals in delivering better patient outcomes and expediting recovery.

LabConnect

Series A in 2017
LabConnect, LLC is a provider of central laboratory services tailored for the biopharmaceutical industry, medical device companies, and contract research organizations. Founded in 2002 and based in Johnson City, Tennessee, LabConnect offers a broad range of services, including routine testing in clinical chemistry, hematology, and infectious diseases, as well as specialized testing in areas such as molecular diagnostics and oncology. The company also provides pathology services, biostorage, sample tracking, and project management, alongside a Global Sample Processing Network that supports sample preparation and processing needs. LabConnect enhances its offerings with advanced technology, including the BioVisualization software platform, which allows real-time analysis of clinical sample data. With laboratories located in various regions, including the United States, Europe, and Asia, LabConnect is strategically positioned to serve both major and emerging markets in the drug development sector.

Empire Genomics

Series B in 2016
Empire Genomics, LLC is a biotechnology company specializing in molecular and cytogenetic diagnostics aimed at understanding the genetic underpinnings of diseases, particularly in oncology. Founded in 2006 and based in Buffalo, New York, with an additional office in Williamsville, the company develops advanced technologies for genome-wide analyses. Empire Genomics offers a range of products, including fluorescence in situ hybridization (FISH) probes, bacterial artificial chromosomes (BAC) clones, and various clinical testing services that encompass flow cytometry, cytogenetics, and next-generation sequencing (NGS). Its comprehensive assay services support healthcare providers in diagnosing and guiding precise therapeutic treatments for patients with cancer and other complex diseases. The company also emphasizes customer support and has established strategic partnerships with notable organizations in the industry. Through its online store and global distribution network, Empire Genomics delivers its innovative solutions to customers worldwide.

Rubicon Genomics

Venture Round in 2015
Rubicon Genomics, Inc. is a biotechnology company based in Ann Arbor, Michigan, specializing in nucleic acid library preparation and amplification technologies that facilitate sensitive analysis of clinical research samples. Founded in 2000 by University of Michigan faculty members, the company focuses on advancing the application of human genetics to practical medicine. Rubicon Genomics offers a range of products, including the ThruPLEX and PicoPLEX kits, which utilize ligation-based and quasi-random primed amplification methods to enhance DNA sequencing and analysis. The company's innovative technologies also include tests designed to detect DNA methylation patterns in cancer cells, providing non-invasive diagnostic options. Rubicon sells its products directly and through distributors, catering to both research and commercial markets, and is committed to supporting the local Michigan economy.

Diagnostic BioSystems

Venture Round in 2015
Diagnostic BioSystems Inc. specializes in the development and provision of innovative immunohistochemistry reagents and systems designed to enhance the practice of anatomic pathology. The company focuses on delivering high-quality products and exceptional customer support. Its extensive product portfolio includes primary and FITC antibodies, autostainers, chromogens, detection kits, and various ancillary items. Diagnostic BioSystems serves both the domestic market and international distributors, reaching customers in over 60 countries worldwide. In addition to reagents, the company also manufactures medical devices, contributing to advancements in in-vitro diagnostics within the anatomic pathology and histology sectors.

Azenta Life Sciences

Venture Round in 2012
Azenta Life Sciences is a global provider of life sciences solutions, focusing on genomics, cryogenic storage, automation, and informatics. The company offers reliable cold-chain sample management solutions and genomic services to support drug development, clinical research, and advanced cell therapies. Azenta serves top pharmaceutical, biotech, academic, and healthcare institutions worldwide, enabling faster breakthroughs and therapies to market.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.